More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies Dec 4, 2008
Auditory (high-frequency hearing loss, decreased hearing) and ocular (lens opacities, cataracts, elevations in intraocular pressure and retinal disorders) disturbances have been reported with Exjade therapy in less than 1% of patients in clinical trials. Auditory and ophthalmic testing (including slit lamp examinations and dilated fundoscopy) are recommended before the start of Exjade treatment and thereafter at regular intervals (every 12 months). (PR Newswire)
Targeting Blood Sugar To Near-normal Levels Increases Risk Of Death In Persons With Diabetes At High Risk, ACCORD Trial Shows Jun 7, 2008
6, 2008) Intensively targeting blood sugar to near-normal levels in adults with type 2 diabetes at especially high risk for heart attack and stroke does not significantly reduce the risk of major cardiovascular events, such as fatal or nonfatal heart attacks or stroke, but increases risk of death, compared to standard treatment. Researchers from the ACCORD (Action to Control Cardiovascular Risk in Diabetes) clinical trial compared a medical strategy aimed at near-normal blood sugar levels --... (Science Daily)
O'Ree remains cool-as-ice puck pioneer Mar 2, 2008
The West Coast proved a blessing for O'Ree, who was converted to right wing by the Blades and found that the retinal disorder was much less of a problem as he took to shooting his wrister from the other side. I only played one game against him and he got a goal on me, said Bobby Champoux, a former Gulls goalie who's now a computer analyst at UCSD. He was just so, so quick. (San Diego Union-Tribune -- Sports)
Researchers query FDA about updating requirements for drug approval Feb 1, 2008
The discussion among the 30 participants focused on endpoints and clinical trial strategies for evaluating new treatments for age-related macular degeneration (AMD), diabetic retinopathy and other severe retinal disorders. The exchange is the subject of Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium, an article in the February 2008 issue of ARVOs peer-reviewed journal, Investigative Ophthalmology and Visual Science (). (EurekAlert!)
Advanced Cell wraps up private placement Sep 5, 2007
The company, which uses stem cell technology, is focused on treatments for heart disease and retinal disorders. It has another office in Worcester, Mass. (East Bay Business Times, CA)
Hailing an essential oil Jul 2, 2007
Inflammation exists not only at the core of heart disease, but also neurological conditions, several pain syndromes, retinal disorders and even some forms of cancer. Dr. Eric Shi of the Feinstein Institute for Medical Research in Manhasset is investigating whether omega-3s might play a role in the prevention of breast cancer. (Newsday -- Health)
ThromboGenics Initiates Phase IIb U.S. Clinical Trial of Microplasmin in Vitrectomy Jan 8, 2007
Desire Collen, CEO of ThromboGenics, commenting on today's announcement, said: "Initiation of these two studies before the end of 2006 demonstrates our commitment to advancing microplasmin in the eye field so that we can capture this exciting product's broad potential. The decision to move forward quickly is based on encouraging safety and efficacy results obtained from the Phase IIa trial (MIVI I) which evaluated Microplasmin in vitrectomy in Europe. These results support not only advancement... (PR Newswire)
